Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study
Authors:
Open Access
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in BMC Anesthesiology
- Vol. 21 (1) , 1-11
Abstract
Background: Intraoperative blood salvage (IBS) is regarded as an alternative to allogeneic blood transfusion excluding the risks associated with allogeneic blood. Currently, IBS is generally avoided in tumor surgeries due to concern for potential metastasis caused by residual tumor cells in the erythrocyte concentrate.Methods: The feasibility, efficacy and safety aspects of the new developedCatuvabprocedure using the bispecific trifunctional antibody Catumaxomab was investigated in an ex-vivo pilot study in order to remove residual EpCAM positive tumor cells from the autologous erythrocyte concentrates (EC) from various cancer patients, generated by a IBS device.Results: Tumor cells in intraoperative blood were detected in 10 of 16 patient samples in the range of 69–2.6 × 105but no residual malignant cells in the final erythrocyte concentrates afterCatuvabprocedure. IL-6 and IL-8 as pro-inflammatory cytokines released during surgery, were lowered in mean 28-fold and 52-fold during theCatuvabprocedure, respectively, whereas Catumaxomab antibody was detected in 8 of 16 of the final EC products at a considerable decreased and uncritical residual amount (37 ng in mean).Conclusion: The preliminary study results indicate efficacy and feasibility of the new medical deviceCatuvaballowing potentially the reinfusion of autologous erythrocyte concentrates (EC) produced by IBS device during oncological high blood loss surgery. An open-label, multicenter clinical study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using theCatuvabdevice is initiated to validate these encouraging results.Keywords
All Related Versions
Funding Information
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
This publication has 39 references indexed in Scilit:
- The Impact of Perioperative Blood Transfusion on Cancer Recurrence and Survival Following Radical CystectomyEuropean Urology, 2013
- EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisJournal of Clinical Pathology, 2011
- Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsBritish Journal of Clinical Pharmacology, 2010
- Transfusion-related immunomodulation (TRIM): An updateBlood Reviews, 2007
- Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerBritish Journal of Cancer, 2007
- Failed evidence of tumour cell removal from salvaged blood after leucocyte depletionTransfusion Medicine, 2006
- Can a leukocyte depletion filter (LDF) reduce the risk of reintroduction of hepatocellular carcinoma cells?Liver Transplantation, 2005
- Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)Journal of Histochemistry & Cytochemistry, 2001
- Separation of malignant cells during autotransfusionBritish Journal of Surgery, 1988
- On Re-Infusion of Blood in Primary and Other AmputationsBMJ, 1886